at page 146, line 31, in "thatwould", insert a space between "that" and "would";

at page 153, line 9, replace "nacceptable" with —unacceptable—;

at page 165, line 2, replace the apostrophes around "primed" with quotation marks;

at page 165, line 15, replace the apostrophes around "Preactivation" with quotation marks;

at page 166, line 17, insert a space between "intake" and "can";

at page 166, line 20, replace the apostrophes around "preactivation" with quotation marks;

at page 166, line 26, replace "exhitibs" with —exhibits—;

IN THE CLAIMS:

Please cancel claim 37 without prejudice or disclaimer.

Please amend claims 17, 20, 30, 31, 35 and 36 as follows:

17.   The method of claim 10, wherein the [disorder] <u>disease or condition</u> is selected from the group consisting of myocardial infarction, stroke, hemorrhagic shock, diabetic retinopathy, diabetes, and venous insufficiency.

20.   The method of claim 19, wherein the protease <u>inhibitor</u> is a serine protease <u>inhibitor</u>.

30.   The method of claim [28] <u>29</u>, wherein the cells are endothelial cells.

31.   The method of claim [28] <u>29</u>, wherein the cells are contacted with the composition prior to contacting the cells with the compound.

35.   The method of claim [32] <u>34</u>, wherein the protease inhibitor is a serine protease inhibitor.

36.   The method of claim [32] <u>34</u>, wherein the protease inhibitor is selected from among α_1-proteinase inhibitor (α_1-antitrypsin), α_2-macroglobin, inter-α_1-trypsin inhibitor, and α_1-antichymotrypsin.